Literature DB >> 20804540

Erythropoietin is involved in angiogenesis in human primary melanoma.

Domenico Ribatti1, Beatrice Nico, Maria Teresa Perra, Vito Longo, Cristina Maxia, Tiziana Annese, Franca Piras, Daniela Murtas, Paola Sirigu.   

Abstract

In this study, the extent of angiogenesis, evaluated as microvascular volume density, immunoreactivity of tumour cells to erythropoietin (Epo) and of endothelial cells to Epo receptor (EpoR) have been correlated in human primary melanoma specimens. Results showed that Epo/EpoR expression correlate with angiogenesis and tumour thickness. These findings suggest that Epo is secreted by tumour cells and it affects vascular endothelial cells via its receptor and promotes angiogenesis in a paracrine manner, playing an important role in melanoma angiogenesis.
© 2010 The Authors. International Journal of Experimental Pathology © 2010 International Journal of Experimental Pathology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20804540      PMCID: PMC3010547          DOI: 10.1111/j.1365-2613.2010.00731.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  46 in total

1.  Angiogenesis correlates with metastasis in melanoma.

Authors:  L T Neitzel; C D Neitzel; K L Magee; M P Malafa
Journal:  Ann Surg Oncol       Date:  1999 Jan-Feb       Impact factor: 5.344

2.  Fine-structure epitope mapping of antierythropoietin monoclonal antibodies reveals a model of recombinant human erythropoietin structure.

Authors:  S Elliott; T Lorenzini; D Chang; J Barzilay; E Delorme; J Giffin; L Hesterberg
Journal:  Blood       Date:  1996-04-01       Impact factor: 22.113

3.  C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2.

Authors:  M O Hengartner; H R Horvitz
Journal:  Cell       Date:  1994-02-25       Impact factor: 41.582

4.  Expression of the erythropoietin receptor by trophoblast cellsin the human placenta.

Authors:  D Fairchild Benyo; K P Conrad
Journal:  Biol Reprod       Date:  1999-04       Impact factor: 4.285

5.  In situ detection of basic fibroblast growth factor by highly specific antibodies.

Authors:  K Schulze-Osthoff; W Risau; E Vollmer; C Sorg
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

6.  Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression.

Authors:  J A Reed; N S McNutt; J K Bogdany; A P Albino
Journal:  J Cutan Pathol       Date:  1996-12       Impact factor: 1.587

7.  Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus.

Authors:  S E Juul; A T Yachnis; R D Christensen
Journal:  Early Hum Dev       Date:  1998-10       Impact factor: 2.079

8.  Tumor vascularity is not a prognostic factor for malignant melanoma of the skin.

Authors:  K J Busam; M Berwick; K Blessing; K Fandrey; S Kang; T Karaoli; J Fine; A J Cochran; W L White; J Rivers
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

9.  A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.

Authors:  Kimberly A Varker; Jennifer E Biber; Cheryl Kefauver; Rhonda Jensen; Amy Lehman; Donn Young; Haifeng Wu; Gregory B Lesinski; Kari Kendra; Helen X Chen; Michael J Walker; William E Carson
Journal:  Ann Surg Oncol       Date:  2007-05-30       Impact factor: 5.344

10.  Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts.

Authors:  T Oku; J G Tjuvajev; T Miyagawa; T Sasajima; A Joshi; R Joshi; R Finn; K P Claffey; R G Blasberg
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

View more
  9 in total

1.  Functional involvement of β3-adrenergic receptors in melanoma growth and vascularization.

Authors:  Massimo Dal Monte; Giovanni Casini; Luca Filippi; Grazia Paola Nicchia; Maria Svelto; Paola Bagnoli
Journal:  J Mol Med (Berl)       Date:  2013-08-02       Impact factor: 4.599

2.  Erythropoietin and erythropoietin receptor in hepatocellular carcinoma: correlation with vasculogenic mimicry and poor prognosis.

Authors:  Zhihong Yang; Baocun Sun; Xiulan Zhao; Bing Shao; Jindan An; Qiang Gu; Yong Wang; Xueyi Dong; Yanhui Zhang; Zhiqiang Qiu
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

3.  Epigenetic silencing of erythropoietin in human cancers.

Authors:  Katrin Steinmann; Antje M Richter; Reinhard H Dammann
Journal:  Genes Cancer       Date:  2011-01

4.  Transient and Efficient Vascular Permeability Window for Adjuvant Drug Delivery Triggered by Microbeam Radiation.

Authors:  Sarah Sabatasso; Cristian Fernandez-Palomo; Ruslan Hlushchuk; Jennifer Fazzari; Stefan Tschanz; Paolo Pellicioli; Michael Krisch; Jean A Laissue; Valentin Djonov
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

Review 5.  Epoetin beta for the treatment of chemotherapy-induced anemia: an update.

Authors:  Luca Galli; Clara Ricci; Colin Gerard Egan
Journal:  Onco Targets Ther       Date:  2015-03-05       Impact factor: 4.147

Review 6.  Erythropoietin and cancer: the unintended consequences of anemia correction.

Authors:  Nataša Debeljak; Peter Solár; Arthur J Sytkowski
Journal:  Front Immunol       Date:  2014-11-11       Impact factor: 7.561

Review 7.  Erythropoietin and Its Angiogenic Activity.

Authors:  Patrícia Kimáková; Peter Solár; Zuzana Solárová; Radovan Komel; Nataša Debeljak
Journal:  Int J Mol Sci       Date:  2017-07-13       Impact factor: 5.923

8.  Vasculogenic Mimicry Formation Is Associated with Erythropoietin Expression but Not with Erythropoietin Receptor Expression in Cervical Squamous Cell Carcinoma.

Authors:  Yue-Jie Li; Xin Qing; Qing-Xu Tao; Li Xiang; Li Gong; Tie-Jun Zhou
Journal:  Biomed Res Int       Date:  2019-02-21       Impact factor: 3.411

9.  The effect of erythropoietin on normal and neoplastic cells.

Authors:  Steve Elliott; Angus M Sinclair
Journal:  Biologics       Date:  2012-06-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.